Sareum Holdings PLCFRA Sareum Holdings Stock Report

Sareum Holdings Plc engages in the discovery and development of drug candidates for the treatment of cancers and autoimmune diseases. The company is headquartered in Cambridge, Cambridgeshire and currently employs 5 full-time employees. The company went IPO on 2004-10-11. The firm is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The firm is focused advancing the dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the cytokine storm immune system overreaction to Covid-19 and other viral infections (SDC-1801) and cancer immunotherapy (SDC-1802). The firm has interest in SRA737, which is a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and deoxyribonucleic (DNA) damage repair mechanisms. In addition, the Company manufactures SDC-1801 drug substance and oral capsule formulation under good manufacturing practice (GMP) conditions is on track to enable the Phase Ia trial.